Dana Boyle, serving as the Chief Accounting Officer at Liquidia Corp (NASDAQ:LQDA), has completed the sale of 9,002 shares of the company's common stock. This transaction, finalized on July 13, 2026, generated a total proceeds value of $643,739. The execution of these sales occurred within a specific price range, with shares transacting between $71.39 and $71.52 per unit.
The divestment was carried out in accordance with a Rule 10b5-1 trading plan, which Boyle established on December 15, 2023. The primary purpose of these transactions was to satisfy tax liabilities associated with the settlement of restricted stock units and performance stock units. These equity awards were originally granted to Boyle across various dates in 2024 and 2025. Prior to executing this sale, Boyle had acquired 3,179 shares of common stock on July 10, 2026. This acquisition occurred through the vesting of performance stock units, which convert into common stock on a one-for-one basis.
Following the completion of these transactions, Boyle's direct ownership of Liquidia common stock totals 169,519 shares. This holding encompasses a variety of equity instruments, including unvested restricted stock units and performance stock units, as well as shares obtained through the Liquidia Corporation 2020 Employee Stock Purchase Plan. Market data indicates that the stock has appreciated significantly, rising to $76.47. This movement reflects a substantial 427% gain over the past year. However, the stock has experienced a recent correction, dipping approximately 4% over the last week.
In the broader corporate landscape, Liquidia Corporation has recently drawn attention due to its announcement to join the S&P SmallCap 600 Index. This inclusion is scheduled to take effect prior to the opening of trading on June 22, marking a notable structural development for the firm. Additionally, analyst sentiment and projections have seen adjustments. BofA Securities recently downgraded Liquidia's stock rating from Buy to Neutral. Despite the rating change, the firm raised its price target from $64 to $79. This revision followed the launch of the drug Yutrepia, which exceeded expectations and prompted a revised peak sales estimate of $2.2 billion.
Other institutional perspectives have also been noted. H.C. Wainwright increased its price target for Liquidia to $75 while maintaining a Buy rating. This adjustment was influenced by a favorable Supreme Court ruling that could positively impact Liquidia's ongoing legal case. Similarly, Raymond James reiterated a Strong Buy rating with a $68 price target, also citing the Supreme Court decision as beneficial for the company. These developments highlight the evolving market position of Liquidia and the varied analyst perspectives on its future trajectory.
Market analysis platforms, such as InvestingPro, suggest that the stock appears undervalued based on Fair Value analysis. Investors seeking further insights can access comprehensive analysis through the platform's Pro Research Report for LQDA, which includes additional ProTips. The stock currently trades at 76.465, reflecting a positive movement of +5.255 (+7.38%) as of the last close. After-hours trading shows a slight decline to 75.50, down -0.990 (-1.29%).